About C-X-C chemokine receptor type 2
C-X-C chemokine receptor type 2 (CXCR2) is a protein
from Homo sapiens identified by UniProt accession
P25025, 360 residues long.
MolForge cross-references it against 0 known binders and
951 disease associations.
Target properties
| Protein name | C-X-C chemokine receptor type 2 |
| UniProt accession | P25025 |
| Gene | CXCR2 |
| Organism | Homo sapiens |
| Length | 360 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (2)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (951)
Diseases linked to this target (Open Targets).
- neutrophil count · score 0.58
- leukocyte count · score 0.58
- neutrophil percentage of leukocytes · score 0.57
- lymphocyte percentage of leukocytes · score 0.56
- monocyte percentage of leukocytes · score 0.54
- type 1 diabetes mellitus · score 0.35
- ulcerative colitis · score 0.29
- glioblastoma multiforme · score 0.28
- pneumonia · score 0.28
- COVID-19 · score 0.27
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P25025-F1 | alphafold | PREDICTED | 79.58 | — |
Amino-acid sequence (360 residues)
MEDFNMESDS FEDFWKGEDL SNYSYSSTLP PFLLDAAPCE PESLEINKYF VVIIYALVFL LSLLGNSLVM LVILYSRVGR SVTDVYLLNL ALADLLFALT LPIWAASKVN GWIFGTFLCK VVSLLKEVNF YSGILLLACI SVDRYLAIVH ATRTLTQKRY LVKFICLSIW GLSLLLALPV LLFRRTVYSS NVSPACYEDM GNNTANWRML LRILPQSFGF IVPLLIMLFC YGFTLRTLFK AHMGQKHRAM RVIFAVVLIF LLCWLPYNLV LLADTLMRTQ VIQETCERRN HIDRALDATE ILGILHSCLN PLIYAFIGQK FRHGLLKILA IHGLISKDSL PKDSRPSFVG SSSGHTSTTL
Explore C-X-C chemokine receptor type 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets